Keranil6%

Keranil is a topical keratolytic (skin-peeling) agent used for a range of hyperkeratotic and scaling skin conditions. Its evidence and approved uses vary by concentration and formulation (gel, lotion, shampoo, plaster/pad, cream).

Established/FDA-recognized (OTC) uses

• Acne vulgaris - low concentrations (0.5%-2%) as a topical acne treatment to unclog pores and reduce comedones.
• Common, plantar, and flat warts - higher concentrations (up to 17-40%) as an over-the-counter wart remover.
• Dandruff and seborrheic dermatitis of the scalp - medicated shampoos to reduce scaling.
• Corns and calluses - higher-strength plasters/pads to soften and remove thickened skin.

Guideline-supported/adjunct uses

• Psoriasis (scalp and body plaques) - used as a keratolytic adjunct to remove scale and improve penetration of other topical agents (e.g., corticosteroids, vitamin D analogues); not a treatment for the underlying disease itself.
• Ichthyosis and other hyperkeratotic skin disorders - as an adjunctive keratolytic under medical supervision.

Off-label/other use

• Chemical peels for photoaging and hyperpigmentation (higher-concentration professional/in-office formulations, typically 20-30%), performed under professional supervision.

Each formulation of Salicylic Acid contains Salicylic Acid as the active ingredient in a concentration appropriate to its intended use, ranging from approximately 0.5% to 2% in acne washes/gels, 2%-3% in dandruff shampoos and psoriasis preparations, and 17% to 40% in wart-removal products and corn/callus plasters. It is formulated in vehicles such as gel, lotion, cream, foaming cleanser, medicated shampoo, collodion-based liquid, or adhesive plaster, often combined with excipients that aid penetration and skin adherence.

Keranil is a beta-hydroxy acid (BHA) derived from willow bark and related plants, used topically for its keratolytic (skin-softening and exfoliating) properties. It works by dissolving the intercellular cement that holds dead skin cells together, promoting shedding of the outer skin layer (desquamation) and softening of thickened, hardened, or excess keratin.

Keranil is available in numerous non-prescription and prescription-strength formulations for acne, warts, corns, calluses, dandruff, seborrheic dermatitis, and psoriasis, and it is also used at higher concentrations in professional chemical peels.

Topical keratolytic agent; Beta-hydroxy acid (BHA); Anti-acne and anti-dandruff/anti-psoriatic topical preparation.

Salicylic Acid exerts its keratolytic effect by dissolving the intercellular cementing substance that binds corneocytes within the stratum corneum, causing the outer layer of skin to soften, loosen, and shed. This reduces the thickness of hyperkeratotic skin (as in warts, corns, and calluses), helps clear follicular plugging in acne, and lifts adherent scale in dandruff, seborrheic dermatitis, and psoriasis.

At low concentrations it also has mild comedolytic and anti-inflammatory properties useful in acne. At higher concentrations used in chemical peels, it penetrates into the epidermis, is self-limiting due to precipitation on the skin surface ("frosting"), and promotes epidermal renewal. A small fraction of applied Salicylic Acid is absorbed systemically and metabolized similarly to orally administered salicylates, which is clinically relevant only with extensive application over large body surface areas or under occlusion.

For external/topical use only. Wash and dry the area before application. Apply only to the affected skin, avoiding healthy surrounding skin, eyes, lips, mucous membranes, and open wounds. Do not apply to large body surface areas or use with other irritant topical products (e.g., retinoids, benzoyl peroxide) simultaneously without medical advice, as this increases irritation. Wash hands after application unless hands are the treated area.

Keranil is primarily used topically, so systemic drug interactions are uncommon but can occur with extensive application or in combination with other topical/systemic agents:

• Other topical keratolytics/irritants (e.g., benzoyl peroxide, tretinoin, other retinoids, alpha-hydroxy acids, sulfur, resorcinol): concurrent use increases the risk of additive skin irritation, dryness, and peeling.
• Oral salicylates/aspirin or other NSAIDs: theoretical additive risk of systemic salicylate toxicity if Keranil is applied over large areas, especially in patients already taking these medicines.
• Oral hypoglycemic agents (sulfonylureas) and methotrexate: high systemic salicylate absorption (from extensive topical use) may theoretically potentiate these drugs' effects; clinically significant only with substantial systemic absorption.

Local skin reactions are the most common adverse effects of Keranil and are usually dose- and concentration-dependent:

• Application-site burning, stinging, or redness (common, especially on first use).
• Dryness, peeling, and mild irritation of treated skin.
• Contact dermatitis or allergic skin reaction (uncommon).
• Hypopigmentation or hyperpigmentation, particularly in darker skin tones (uncommon).
• Skin ulceration or chemical burn with excessive concentration, prolonged contact, or use on compromised skin (rare, dose-related).
• Salicylate toxicity (tinnitus, nausea, vomiting, hyperventilation, confusion) - rare, occurring only with extensive application over large surface areas, prolonged occlusive use, or in young children.

Topical Keranil, when used on limited areas as directed, results in minimal systemic absorption; however, formal safety data in pregnancy and lactation are limited. As a general precaution, Keranil should be used during pregnancy and breastfeeding only if clearly needed, at the lowest effective concentration and over the smallest area, and only after consulting a physician, since higher-concentration or extensive-area use could result in systemic salicylate absorption. Application to the breast area should be avoided while breastfeeding to prevent inadvertent infant ingestion.

Use Keranil only as directed on the product label or by a physician. Avoid contact with eyes, lips, mouth, mucous membranes, and normal skin surrounding the treated area; rinse thoroughly with water if accidental contact occurs. Do not apply to large areas of the body or use for prolonged periods without medical supervision, as this increases the risk of systemic salicylate absorption and toxicity, particularly in children, the elderly, and patients with renal or hepatic impairment. Avoid use in children with chickenpox or influenza-like viral illness due to a theoretical association between salicylates and Reye's syndrome, although the systemic absorption from typical topical use is far lower than with oral aspirin. Discontinue use and consult a physician if excessive skin irritation, redness, swelling, or signs of infection develop. Do not use with a heating pad or bandage that increases absorption unless directed. Avoid concurrent use with other potentially irritating topical products unless advised by a physician.

Overdose or salicylate toxicity from topical Keranil is uncommon but can occur with extensive application over large body surface areas, prolonged occlusive use, or accidental ingestion. Symptoms may include ringing in the ears (tinnitus), nausea, vomiting, rapid or deep breathing, confusion, dizziness, or drowsiness. If accidental ingestion occurs or symptoms of systemic toxicity develop, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment for suspected salicylate toxicity.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Keep the container tightly closed and avoid exposure to excessive heat or direct sunlight.

Elderly: Use with caution; elderly patients may have thinner skin and reduced peripheral circulation, increasing risk of irritation, ulceration, or systemic absorption - avoid use on the feet without medical supervision, especially with diabetes or vascular disease.

Renal or hepatic impairment: Use with caution and avoid extensive application, as impaired clearance of absorbed salicylate could increase systemic toxicity risk.

Diabetic patients: Avoid self-treatment of foot warts, corns, or calluses with Keranil; use only under direct medical supervision due to risk of poor wound healing and ulceration.

Duration varies by indication: acne preparations are typically used continuously for 6-12 weeks to assess benefit; wart-removal regimens are generally continued daily for up to 12 weeks or until the wart resolves; dandruff/seborrheic dermatitis shampoos are used 2-3 times weekly on an ongoing basis; psoriasis scale-softening use should follow physician direction. If no improvement is seen within the expected timeframe, or if irritation develops, discontinue and consult a physician.

Keratolytic agents; Beta-hydroxy acids (BHA); Topical anti-acne agents; Topical anti-psoriatic/anti-dandruff agents.

Salicylic Acid acts by dissolving the intercellular cement (desmosomal attachments) between corneocytes in the stratum corneum, leading to controlled desquamation of the outer skin layer. This reduces hyperkeratosis, softens thickened skin (as in warts, corns, and calluses), unclogs pilosebaceous follicles in acne, and loosens adherent scale in dandruff, seborrheic dermatitis, and psoriasis.

Use of Keranil in children requires caution due to a larger body-surface-area-to-weight ratio, which increases the risk of systemic salicylate absorption and toxicity compared with adults. Low-concentration acne products are generally not recommended below the age indicated on product labeling (commonly 12 years for many OTC formulations, per manufacturer directions). Wart-removal products at higher concentrations should be used in children only under adult supervision, applied strictly to the wart, and for limited duration. Keranil should not be used in infants under 2 years of age unless directed by a physician, and should be avoided in children with chickenpox or flu-like illness due to a theoretical Reye's syndrome concern. Safety and efficacy of higher-concentration professional peel formulations have not been established in children.